Risk of diabetic retinopathy and ophthalmic interventions in patients with diabetes mellitus taking different oral anticoagulants
Authors' conclusion
Taking NOACs was associated with lower risks of developing DM-related ocular complications than taking warfarin in patients with DM.
Study context
- Population
- Patients with diabetes mellitus (DM) initiated on NOACs or warfarin (TriNetX)Propensity score matching (PSM) cohorts
- Participants
- 122,979 vs 122,979
- Exposure
- NOACs vs warfarin
- NOACsn = 122,979
- Warfarinn = 122,979reference
- Outcome
- DR
- Follow-up
- 6 months, 1 year, 3 years and 5 years
Methodological detailspropensity score matched, TriNetX
- Propensity score matched
- TriNetX
Main finding
As reported in the abstract
NOACs vs WarfarinHazard ratio (95% CI)
6 months
0.66(0.60–0.72)
1 year
0.68(0.63–0.73)
3 years
0.70(0.67–0.74)
5 years
0.73(0.70–0.76)
Observational data: associations, not effects.
Secondary outcomes
Proliferative DR (PDR), DME and need for treatment of vision-threatening diabetic retinopathy (DR) · 6 months, 1 year, 3 years and 5 years
- Lower risks with NOACs extended to all secondary endpoints across all follow-up intervals
Original publication
Risk of diabetic retinopathy and ophthalmic interventions in patients with diabetes mellitus taking different oral anticoagulants. Diabetes Obes Metab. Published 28 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →